Seoul: South Korea’s major pharmaceutical companies spent around 100 billion won ($72.13 million) each in the first half for the research and development (R&D) of new drugs, data showed on Sunday, in an apparent bid to secure future growth engines. Yuhan Corp., famous for its anti-inflammatory ointment Antiphlamine, said in a regulatory filing that it.
